<article xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="EN" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neurooncol</journal-id><journal-title>Journal of Neuro-Oncology</journal-title><issn pub-type="ppub">0167-594X</issn><issn pub-type="epub">1573-7373</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>Boston</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19169651</article-id><article-id pub-id-type="pmc">2687520</article-id><article-id pub-id-type="publisher-id">9781</article-id><article-id pub-id-type="doi">10.1007/s11060-008-9781-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study - Patient Study</subject></subj-group></article-categories><title-group><article-title>Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Lim</surname><given-names>Daniel A.</given-names></name><address><email>limd@neurosurg.ucsf.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tarapore</surname><given-names>Phiroz</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chang</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burt</surname><given-names>Marlene</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chakalian</surname><given-names>Lenna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barbaro</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chang</surname><given-names>Susan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lamborn</surname><given-names>Kathleen R.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>McDermott</surname><given-names>Michael W.</given-names></name><address><phone>+415-353-3489</phone><fax>+415-353-3907</fax><email>mcdermottm@neurosurg.ucsf.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Neurological Surgery, University of California, 505 Parnassus Ave. M779, San Francisco, CA 94143 USA </aff><aff id="Aff2"><label>2</label>Surgical Service, Department of Veterans Affairs Medical Center, San Francisco, CA USA </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>1</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2009</year></pub-date><volume>93</volume><issue>3</issue><fpage>349</fpage><lpage>354</lpage><history><date date-type="received"><day>19</day><month>10</month><year>2008</year></date><date date-type="accepted"><day>30</day><month>12</month><year>2008</year></date></history><permissions><copyright-statement>© The Author(s) 2009</copyright-statement></permissions><abstract xml:lang="EN"><p><offsets xml_i="3629" xml_f="4996" txt_i="11" txt_f="1378">Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures. PHT, however, has many undesirable side effects (SEs) and drug interactions with glioma chemotherapy. Levetiracetam (LEV) is a newer antiepileptic drug (AED) with fewer SEs and essentially no drug interactions. We performed a pilot study testing the safety and feasibility of switching patients from PHT to LEV monotherapy for postoperative control of glioma-related seizures. Over a 13-month period, 29 patients were randomized in a 2:1 ratio to initiate LEV therapy within 24 h of surgery or to continue PHT therapy. 6 month follow-up data were available for 15 patients taking LEV and for 8 patients taking PHT. In the LEV group, 13 patients (87%) were seizure-free. In the PHT group, 6 patients (75%) were seizure-free. Reported SEs at 6 months was as follows (%LEV/%PHT group): dizziness (0/14), difficulty with coordination (0/29), depression (7/14) lack of energy or strength (20/43), insomnia (40/43), mood instability (7/0). The pilot data presented here suggest that it is safe to switch patients from PHT to LEV monotherapy following craniotomy for supratentorial glioma. A large-scale, double-blinded, randomized control trial of LEV versus PHT is required to determine seizure control equivalence and better assess differences in SEs.</offsets></p></abstract><kwd-group><title>Keywords</title><kwd>Seizure</kwd><kwd>Anticonvulsant</kwd><kwd>Glioma</kwd><kwd>Levitiracetam</kwd><kwd>Phenytoin</kwd><kwd>Craniotomy</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer Science+Business Media, LLC. 2009</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title><offsets xml_i="5438" xml_f="5450" txt_i="1386" txt_f="1398">Introduction</offsets></title><p><offsets xml_i="5461" xml_f="5536" txt_i="1399" txt_f="1474">At diagnosis, ~20–40% of all brain tumor patients will have had a seizure [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="5568" xml_f="5569" txt_i="1474" txt_f="1475">1</offsets></xref><offsets xml_i="5576" xml_f="5638" txt_i="1475" txt_f="1537">] that may result in morbidity and decreased quality of life [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="5670" xml_f="5671" txt_i="1537" txt_f="1538">2</offsets></xref><offsets xml_i="5678" xml_f="5817" txt_i="1538" txt_f="1677">]. Thus, treatment with antiepileptic drugs (AEDs) is clearly indicated for brain tumor patients with preoperative tumor-related seizures [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="5849" xml_f="5850" txt_i="1677" txt_f="1678">3</offsets></xref><offsets xml_i="5857" xml_f="5858" txt_i="1678" txt_f="1679">–</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="5890" xml_f="5891" txt_i="1679" txt_f="1680">5</offsets></xref><offsets xml_i="5898" xml_f="6073" txt_i="1680" txt_f="1855">]. Surgical treatment of brain tumors is also associated with a high risk of postoperative seizures. Approximately, one-third of patients have seizures after tumor resection [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="6105" xml_f="6106" txt_i="1855" txt_f="1856">6</offsets></xref><offsets xml_i="6113" xml_f="6114" txt_i="1856" txt_f="1857">–</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="6146" xml_f="6147" txt_i="1857" txt_f="1858">8</offsets></xref><offsets xml_i="6154" xml_f="6240" txt_i="1858" txt_f="1944">], and in the case of supratentorial craniotomy, 20%–50% of patients have ≥1 seizure [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="6272" xml_f="6273" txt_i="1944" txt_f="1945">9</offsets></xref><offsets xml_i="6280" xml_f="6282" txt_i="1945" txt_f="1947">, </offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="6315" xml_f="6317" txt_i="1947" txt_f="1949">10</offsets></xref><offsets xml_i="6324" xml_f="6326" txt_i="1949" txt_f="1951">].</offsets></p><p><offsets xml_i="6333" xml_f="6661" txt_i="1952" txt_f="2280">Brain tumor patients who experience tumor-related seizures are often placed on phenytoin (PHT) therapy. Although there are no formal guidelines, it is common practice to continue PHT after craniotomy in these patients. However, PHT has many side effects (SEs) and undesirable interactions with drugs used to treat brain tumors [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="6693" xml_f="6694" txt_i="2280" txt_f="2281">1</offsets></xref><offsets xml_i="6701" xml_f="6703" txt_i="2281" txt_f="2283">, </offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="6736" xml_f="6738" txt_i="2283" txt_f="2285">11</offsets></xref><offsets xml_i="6745" xml_f="6746" txt_i="2285" txt_f="2286">–</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="6779" xml_f="6781" txt_i="2286" txt_f="2288">14</offsets></xref><offsets xml_i="6788" xml_f="6857" txt_i="2288" txt_f="2357">] which can complicate the pharmacological treatment of these tumors.</offsets></p><p><offsets xml_i="6864" xml_f="7059" txt_i="2358" txt_f="2553">Levetiracetam (LEV) is a newer AED that possesses a different pharmacological profile from that of PHT, with no effects on liver enzymes and no known effect on the kinetics of other medications [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="7092" xml_f="7094" txt_i="2553" txt_f="2555">15</offsets></xref><offsets xml_i="7101" xml_f="7103" txt_i="2555" txt_f="2557">, </offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="7136" xml_f="7138" txt_i="2557" txt_f="2559">16</offsets></xref><offsets xml_i="7145" xml_f="7262" txt_i="2559" txt_f="2676">]. Furthermore, other medications including enzyme-inducing AEDs have essentially no effect on LEV pharmacokinetics [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="7295" xml_f="7297" txt_i="2676" txt_f="2678">15</offsets></xref><offsets xml_i="7304" xml_f="7306" txt_i="2678" txt_f="2680">, </offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="7339" xml_f="7341" txt_i="2680" txt_f="2682">17</offsets></xref><offsets xml_i="7348" xml_f="7516" txt_i="2682" txt_f="2850">]. In retrospective studies, LEV has been found to be effective and well tolerated as add-on or monotherapy in patients with either primary or metastatic brain tumors [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="7549" xml_f="7551" txt_i="2850" txt_f="2852">18</offsets></xref><offsets xml_i="7558" xml_f="7560" txt_i="2852" txt_f="2854">, </offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="7593" xml_f="7595" txt_i="2854" txt_f="2856">19</offsets></xref><offsets xml_i="7602" xml_f="7705" txt_i="2856" txt_f="2959">]. Prospectively, LEV has been studied mostly as add-on therapy for persistent tumor-related seizures [</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="7738" xml_f="7740" txt_i="2959" txt_f="2961">20</offsets></xref><offsets xml_i="7747" xml_f="7749" txt_i="2961" txt_f="2963">, </offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="7782" xml_f="7784" txt_i="2963" txt_f="2965">21</offsets></xref><offsets xml_i="7791" xml_f="7869" txt_i="2965" txt_f="3043">], and for this purpose, LEV appears to be safe and feasible and with few SEs.</offsets></p><p><offsets xml_i="7876" xml_f="8393" txt_i="3044" txt_f="3561">Ideally, patients with brain tumor-related seizures would achieve seizure control with an AED that does not negatively interact with adjunctive chemotherapy and has few SEs. However, PHT is still commonly used as a first-line AED in brain tumor patients, and conversion of PHT therapy to LEV monotherapy has not been studied. Therefore, we prospectively studied the safety and feasibility of converting PHT to LEV monotherapy after craniotomy for glioma resection in patients with a history of tumor-related seizures.</offsets></p></sec><sec id="Sec2" sec-type="materials|methods"><title><offsets xml_i="8454" xml_f="8475" txt_i="3563" txt_f="3584">Materials and methods</offsets></title><p><offsets xml_i="8486" xml_f="9112" txt_i="3585" txt_f="4199">Key patient inclusion criteria for the study included: seizure history attributable to supratentorial glioma, PHT monotherapy for seizure prophylaxis, planned craniotomy as standard management, ≤1 previous resection, &gt;18 years of age, Karnofosky performance scale of &gt;70, and no other co-morbidities. Exclusion criteria included: non-glioma cancer, pregnancy or breast-feeding, seizures unrelated to the suspected glioma, use of anticonvulsants or AEDs other than PHT, &gt;1 generalized seizure per day, and prior interstitial brachytherapy. Preoperative labs were examined to ensure that patients had a WBC &gt;3.4 × 10</offsets><sup><offsets xml_i="9117" xml_f="9118" txt_i="4199" txt_f="4200">9</offsets></sup><offsets xml_i="9124" xml_f="9225" txt_i="4200" txt_f="4289">/l, platelets &gt;100,000/l, hemoglobin &gt;10 g/dl, INR &lt;1.3, and serum creatinine &lt;1.5 mg/dl.</offsets></p><p><offsets xml_i="9232" xml_f="10079" txt_i="4290" txt_f="5137">We had planned to enroll 60 patients in this study (40 patients in the LEV group, 20 in the PHT group). This study was designed to be a feasibility study for a potential larger trial. We designed this trial to have met the “feasibility” requirement if seizure control was no more than 20% points worse than historical controls. Because of a diminishing accrual rate, we closed the study after the enrollment of 29 patients. These 29 patients were enrolled over a 13-month period. After signing an approved Institutional Review Board consent form, patients were first stratified into two groups: (1) those with no prior craniotomy, and (2) those with a history of one craniotomy. Within each stratification group, patients were randomized in a 2:1 ratio to initiate LEV therapy within 24 h of surgery or to continue PHT therapy, respectively (Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="10111" xml_f="10112" txt_i="5137" txt_f="5138">1</offsets></xref><offsets xml_i="10119" xml_f="10630" txt_i="5138" txt_f="5649">). Patients randomized to PHT therapy had serum levels confirmed to be in the therapeutic range (10–20 mg/dl) by the first postoperative day (POD1); PHT dosages were adjusted, if necessary. Patient randomized to LEV therapy were started on an oral regimen of LEV 1,000 mg twice a day within 24 h of surgery; in these patients, PHT was tapered off in the following manner: 100% of preoperative PHT regimen on POD0, 75% of PHT regimen on POD1, 50% of PHT regimen on POD2, and PHT therapy was discontinued on POD3.</offsets><fig id="Fig1"><label><offsets xml_i="10652" xml_f="10658" txt_i="5649" txt_f="5655">Fig. 1</offsets></label><caption><p><offsets xml_i="10678" xml_f="10814" txt_i="5655" txt_f="5791">Schematic showing trial design. Patients in the LEV treatment arm (left) were tapered off of PHT therapy over the course of 3 days. See </offsets><xref rid="Sec2" ref-type="sec"><offsets xml_i="10846" xml_f="10867" txt_i="5791" txt_f="5812">materials and methods</offsets></xref><offsets xml_i="10874" xml_f="10886" txt_i="5812" txt_f="5824"> for details</offsets></p></caption><graphic position="anchor" xlink:href="11060_2008_9781_Fig1_HTML" id="MO1"></graphic></fig></p><p><offsets xml_i="10998" xml_f="11706" txt_i="5826" txt_f="6534">Patients were to be followed postoperatively for 6 months, during which their medical charts were reviewed and two standardized telephone surveys were conducted at ~3-month intervals. Patients were provided with seizure diaries and a 24-h pager number to alert study personnel of any seizures or AED-related SEs. Seizure frequency data were based on patient-initiated contact of study personnel (through use of the 24-h pager), the telephone surveys, and review of medical charts. The primary end point was the proportion of patients who were seizure free 6 months after tumor resection. Data on AED-related SEs were collected with use of the telephone survey specifically addressing the SEs listed in Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="11740" xml_f="11741" txt_i="6534" txt_f="6535">3</offsets></xref><offsets xml_i="11748" xml_f="11749" txt_i="6535" txt_f="6536">.</offsets></p></sec><sec id="Sec3" sec-type="results"><title><offsets xml_i="11800" xml_f="11807" txt_i="6538" txt_f="6545">Results</offsets></title><p><offsets xml_i="11818" xml_f="11882" txt_i="6546" txt_f="6610">Characteristics of the study population are summarized in Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="11916" xml_f="11917" txt_i="6610" txt_f="6611">1</offsets></xref><offsets xml_i="11924" xml_f="12734" txt_i="6611" txt_f="7421">. Although there were some demographic differences between the two treatment groups, the majority of the study patients were male, suffered from generalized seizures, were diagnosed with glioblastoma, and all underwent craniotomy at the start of the study. One LEV subject died of the primary pathology before the first evaluation. Four other LEV subjects were withdrawn from the study by other physicians who preferred different AEDs; one patient was withdrawn by the neurosurgeon because the patient was a participant in another neuro-oncology trial, and PHT was the standard anticonvulsant in that study; the other three patients were withdrawn from this study by the neurosurgeon because of a personal preference for PHT as the anticonvulsant. One PHT subject could not be located after hospital discharge.</offsets><table-wrap id="Tab1"><label><offsets xml_i="12763" xml_f="12770" txt_i="7421" txt_f="7428">Table 1</offsets></label><caption><p><offsets xml_i="12790" xml_f="12825" txt_i="7428" txt_f="7463">Characteristics of study population</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"></th><th align="left"><offsets xml_i="12926" xml_f="12940" txt_i="7464" txt_f="7478">Total patients</offsets><break></break><offsets xml_i="12955" xml_f="12960" txt_i="7478" txt_f="7483">n (%)</offsets></th><th align="left"><offsets xml_i="12982" xml_f="12994" txt_i="7483" txt_f="7495">LEV patients</offsets><break></break><offsets xml_i="13009" xml_f="13021" txt_i="7495" txt_f="7507">n (% of arm)</offsets></th><th align="left"><offsets xml_i="13043" xml_f="13055" txt_i="7507" txt_f="7519">PHT patients</offsets><break></break><offsets xml_i="13070" xml_f="13082" txt_i="7519" txt_f="7531">n (% of arm)</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="13128" xml_f="13145" txt_i="7531" txt_f="7548">Subjects enrolled</offsets></td><td char="(" align="char"><offsets xml_i="13176" xml_f="13184" txt_i="7549" txt_f="7557">29 (100)</offsets></td><td char="(" align="char"><offsets xml_i="13215" xml_f="13222" txt_i="7558" txt_f="7565">20 (69)</offsets></td><td char="(" align="char"><offsets xml_i="13253" xml_f="13259" txt_i="7566" txt_f="7572">9 (31)</offsets></td></tr><tr><td align="left"><offsets xml_i="13290" xml_f="13331" txt_i="7573" txt_f="7614">Subjects with primary end-point follow-up</offsets></td><td char="(" align="char"><offsets xml_i="13362" xml_f="13369" txt_i="7615" txt_f="7622">23 (79)</offsets></td><td char="(" align="char"><offsets xml_i="13400" xml_f="13407" txt_i="7623" txt_f="7630">15 (75)</offsets></td><td char="(" align="char"><offsets xml_i="13438" xml_f="13444" txt_i="7631" txt_f="7637">8 (89)</offsets></td></tr><tr><td align="left" colspan="4"><italic><offsets xml_i="13495" xml_f="13507" txt_i="7638" txt_f="7650">Demographics</offsets></italic></td></tr><tr><td align="left"><offsets xml_i="13547" xml_f="13553" txt_i="7651" txt_f="7657">Female</offsets></td><td char="(" align="char"><offsets xml_i="13584" xml_f="13590" txt_i="7658" txt_f="7664">6 (26)</offsets></td><td char="(" align="char"><offsets xml_i="13621" xml_f="13627" txt_i="7665" txt_f="7671">6 (40)</offsets></td><td char="(" align="char"><offsets xml_i="13658" xml_f="13659" txt_i="7672" txt_f="7673">0</offsets></td></tr><tr><td align="left"><offsets xml_i="13690" xml_f="13708" txt_i="7674" txt_f="7692">Median age (range)</offsets></td><td char="(" align="char"><offsets xml_i="13739" xml_f="13749" txt_i="7693" txt_f="7703">45 (20–83)</offsets></td><td char="(" align="char"><offsets xml_i="13780" xml_f="13790" txt_i="7704" txt_f="7714">46 (20–56)</offsets></td><td char="(" align="char"><offsets xml_i="13821" xml_f="13831" txt_i="7715" txt_f="7725">39 (32–83)</offsets></td></tr><tr><td align="left" colspan="4"><italic><offsets xml_i="13882" xml_f="13910" txt_i="7726" txt_f="7754">Seizure type at presentation</offsets></italic></td></tr><tr><td align="left"><offsets xml_i="13950" xml_f="13964" txt_i="7755" txt_f="7769">Simple partial</offsets></td><td char="(" align="char"><offsets xml_i="13995" xml_f="14001" txt_i="7770" txt_f="7776">7 (30)</offsets></td><td char="(" align="char"><offsets xml_i="14032" xml_f="14038" txt_i="7777" txt_f="7783">6 (40)</offsets></td><td char="(" align="char"><offsets xml_i="14069" xml_f="14075" txt_i="7784" txt_f="7790">1 (13)</offsets></td></tr><tr><td align="left"><offsets xml_i="14106" xml_f="14121" txt_i="7791" txt_f="7806">Complex partial</offsets></td><td char="(" align="char"><offsets xml_i="14152" xml_f="14158" txt_i="7807" txt_f="7813">5 (22)</offsets></td><td char="(" align="char"><offsets xml_i="14189" xml_f="14194" txt_i="7814" txt_f="7819">1 (7)</offsets></td><td char="(" align="char"><offsets xml_i="14225" xml_f="14231" txt_i="7820" txt_f="7826">4 (50)</offsets></td></tr><tr><td align="left"><offsets xml_i="14262" xml_f="14273" txt_i="7827" txt_f="7838">Generalized</offsets></td><td char="(" align="char"><offsets xml_i="14304" xml_f="14311" txt_i="7839" txt_f="7846">11 (48)</offsets></td><td char="(" align="char"><offsets xml_i="14342" xml_f="14348" txt_i="7847" txt_f="7853">8 (53)</offsets></td><td char="(" align="char"><offsets xml_i="14379" xml_f="14385" txt_i="7854" txt_f="7860">3 (38)</offsets></td></tr><tr><td align="left" colspan="4"><italic><offsets xml_i="14436" xml_f="14443" txt_i="7861" txt_f="7868">Surgery</offsets></italic></td></tr><tr><td align="left"><offsets xml_i="14483" xml_f="14514" txt_i="7869" txt_f="7900">Craniotomy before study surgery</offsets></td><td char="(" align="char"><offsets xml_i="14545" xml_f="14551" txt_i="7901" txt_f="7907">7 (30)</offsets></td><td char="(" align="char"><offsets xml_i="14582" xml_f="14588" txt_i="7908" txt_f="7914">4 (27)</offsets></td><td char="(" align="char"><offsets xml_i="14619" xml_f="14625" txt_i="7915" txt_f="7921">3 (38)</offsets></td></tr><tr><td align="left" colspan="4"><offsets xml_i="14668" xml_f="14688" txt_i="7922" txt_f="7942">Craniotomy for study</offsets></td></tr><tr><td align="left"><offsets xml_i="14719" xml_f="14744" txt_i="7943" txt_f="7968">    Gross total resection</offsets></td><td char="(" align="char"><offsets xml_i="14775" xml_f="14782" txt_i="7969" txt_f="7976">13 (56)</offsets></td><td char="(" align="char"><offsets xml_i="14813" xml_f="14820" txt_i="7977" txt_f="7984">10 (67)</offsets></td><td char="(" align="char"><offsets xml_i="14851" xml_f="14857" txt_i="7985" txt_f="7991">3 (38)</offsets></td></tr><tr><td align="left"><offsets xml_i="14888" xml_f="14910" txt_i="7992" txt_f="8014">    Subtotal resection</offsets></td><td char="(" align="char"><offsets xml_i="14941" xml_f="14948" txt_i="8015" txt_f="8022">10 (43)</offsets></td><td char="(" align="char"><offsets xml_i="14979" xml_f="14985" txt_i="8023" txt_f="8029">5 (33)</offsets></td><td char="(" align="char"><offsets xml_i="15016" xml_f="15022" txt_i="8030" txt_f="8036">5 (63)</offsets></td></tr><tr><td align="left"><italic><offsets xml_i="15061" xml_f="15082" txt_i="8037" txt_f="8058">Final tumor pathology</offsets></italic></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left" colspan="4"><offsets xml_i="15200" xml_f="15211" txt_i="8062" txt_f="8073">WHO grade 1</offsets></td></tr><tr><td align="left"><offsets xml_i="15242" xml_f="15250" txt_i="8074" txt_f="8082">    DNET</offsets></td><td char="(" align="char"><offsets xml_i="15281" xml_f="15286" txt_i="8083" txt_f="8088">1 (4)</offsets></td><td char="(" align="char"><offsets xml_i="15317" xml_f="15322" txt_i="8089" txt_f="8094">1 (7)</offsets></td><td char="(" align="char"><offsets xml_i="15353" xml_f="15354" txt_i="8095" txt_f="8096">0</offsets></td></tr><tr><td align="left" colspan="4"><offsets xml_i="15397" xml_f="15408" txt_i="8097" txt_f="8108">WHO grade 2</offsets></td></tr><tr><td align="left"><offsets xml_i="15439" xml_f="15454" txt_i="8109" txt_f="8124">    Astrocytoma</offsets></td><td char="(" align="char"><offsets xml_i="15485" xml_f="15491" txt_i="8125" txt_f="8131">3 (13)</offsets></td><td char="(" align="char"><offsets xml_i="15522" xml_f="15528" txt_i="8132" txt_f="8138">2 (13)</offsets></td><td char="(" align="char"><offsets xml_i="15559" xml_f="15565" txt_i="8139" txt_f="8145">1 (13)</offsets></td></tr><tr><td align="left"><offsets xml_i="15596" xml_f="15617" txt_i="8146" txt_f="8167">    Oligodendroglioma</offsets></td><td char="(" align="char"><offsets xml_i="15648" xml_f="15653" txt_i="8168" txt_f="8173">2 (9)</offsets></td><td char="(" align="char"><offsets xml_i="15684" xml_f="15689" txt_i="8174" txt_f="8179">1 (7)</offsets></td><td char="(" align="char"><offsets xml_i="15720" xml_f="15726" txt_i="8180" txt_f="8186">1 (13)</offsets></td></tr><tr><td align="left"><offsets xml_i="15757" xml_f="15764" txt_i="8187" txt_f="8194">    PXA</offsets></td><td char="(" align="char"><offsets xml_i="15795" xml_f="15800" txt_i="8195" txt_f="8200">1 (4)</offsets></td><td char="(" align="char"><offsets xml_i="15831" xml_f="15836" txt_i="8201" txt_f="8206">1 (7)</offsets></td><td char="(" align="char"><offsets xml_i="15867" xml_f="15868" txt_i="8207" txt_f="8208">0</offsets></td></tr><tr><td align="left" colspan="4"><offsets xml_i="15911" xml_f="15922" txt_i="8209" txt_f="8220">WHO grade 3</offsets></td></tr><tr><td align="left"><offsets xml_i="15953" xml_f="15968" txt_i="8221" txt_f="8236">    Astrocytoma</offsets></td><td char="(" align="char"><offsets xml_i="15999" xml_f="16005" txt_i="8237" txt_f="8243">4 (17)</offsets></td><td char="(" align="char"><offsets xml_i="16036" xml_f="16042" txt_i="8244" txt_f="8250">4 (27)</offsets></td><td char="(" align="char"><offsets xml_i="16073" xml_f="16074" txt_i="8251" txt_f="8252">0</offsets></td></tr><tr><td align="left"><offsets xml_i="16105" xml_f="16126" txt_i="8253" txt_f="8274">    Oligodendroglioma</offsets></td><td char="(" align="char"><offsets xml_i="16157" xml_f="16162" txt_i="8275" txt_f="8280">1 (4)</offsets></td><td char="(" align="char"><offsets xml_i="16193" xml_f="16194" txt_i="8281" txt_f="8282">0</offsets></td><td char="(" align="char"><offsets xml_i="16225" xml_f="16231" txt_i="8283" txt_f="8289">1 (13)</offsets></td></tr><tr><td align="left"><offsets xml_i="16262" xml_f="16282" txt_i="8290" txt_f="8310">    Oligoastrocytoma</offsets></td><td char="(" align="char"><offsets xml_i="16313" xml_f="16318" txt_i="8311" txt_f="8316">2 (9)</offsets></td><td char="(" align="char"><offsets xml_i="16349" xml_f="16354" txt_i="8317" txt_f="8322">1 (7)</offsets></td><td char="(" align="char"><offsets xml_i="16385" xml_f="16391" txt_i="8323" txt_f="8329">1 (13)</offsets></td></tr><tr><td align="left" colspan="4"><offsets xml_i="16434" xml_f="16445" txt_i="8330" txt_f="8341">WHO grade 4</offsets></td></tr><tr><td align="left"><offsets xml_i="16476" xml_f="16492" txt_i="8342" txt_f="8358">    Glioblastoma</offsets></td><td char="(" align="char"><offsets xml_i="16523" xml_f="16529" txt_i="8359" txt_f="8365">9 (39)</offsets></td><td char="(" align="char"><offsets xml_i="16560" xml_f="16566" txt_i="8366" txt_f="8372">6 (40)</offsets></td><td char="(" align="char"><offsets xml_i="16597" xml_f="16603" txt_i="8373" txt_f="8379">3 (38)</offsets></td></tr></tbody></table><table-wrap-foot><p><italic><offsets xml_i="16657" xml_f="16661" txt_i="8380" txt_f="8384">DNET</offsets></italic><offsets xml_i="16670" xml_f="16711" txt_i="8384" txt_f="8425"> dysembryoplastic neuroepithelial tumor; </offsets><italic><offsets xml_i="16719" xml_f="16722" txt_i="8425" txt_f="8428">PXA</offsets></italic><offsets xml_i="16731" xml_f="16763" txt_i="8428" txt_f="8460"> pleomorphic xanthoastrocytoma; </offsets><italic><offsets xml_i="16771" xml_f="16774" txt_i="8460" txt_f="8463">WHO</offsets></italic><offsets xml_i="16783" xml_f="16837" txt_i="8463" txt_f="8517"> World Health Organization (brain tumor grading scale)</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="16879" xml_f="17027" txt_i="8519" txt_f="8667">Fifteen patients in the LEV group and eight patients in the PHT group were assessed for the primary end point of seizure-freedom at 6 months (Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="17061" xml_f="17062" txt_i="8667" txt_f="8668">2</offsets></xref><offsets xml_i="17069" xml_f="17882" txt_i="8668" txt_f="9481">). Thirteen LEV patients (87%) were free from seizure compared with six PHT patients (75%). During the study period, all patients with follow-up were at least Engel Class 2 (rare seizures). Of the two patients who experienced rare seizures in the LEV group, one patient had stopped taking LEV, and this patient did not suffer additional seizures after resuming therapy; the other patient achieved seizure control with an increased dosage of LEV (1,500 mg twice a day). Most (11/15) LEV patients remained on the initial dose of 1,000 mg twice a day. Three LEV patients were able to lower their dosage to 500 mg twice a day without compromising their complete seizure control. PHT dosages were between 300 and 400 mg per day given as single dose. No patient required hospitalization for seizures or seizure control.</offsets><table-wrap id="Tab2"><label><offsets xml_i="17911" xml_f="17918" txt_i="9481" txt_f="9488">Table 2</offsets></label><caption><p><offsets xml_i="17938" xml_f="17978" txt_i="9488" txt_f="9528">Postoperative seizure status at 6 months</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><offsets xml_i="18057" xml_f="18085" txt_i="9529" txt_f="9557">Seizure status (Engel score)</offsets></th><th align="left"><offsets xml_i="18107" xml_f="18119" txt_i="9557" txt_f="9569">LEV patients</offsets><break></break><offsets xml_i="18134" xml_f="18139" txt_i="9569" txt_f="9574">n (%)</offsets></th><th align="left"><offsets xml_i="18161" xml_f="18173" txt_i="9574" txt_f="9586">PHT patients</offsets><break></break><offsets xml_i="18188" xml_f="18193" txt_i="9586" txt_f="9591">n (%)</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="18239" xml_f="18253" txt_i="9591" txt_f="9605">n at follow-up</offsets></td><td char="(" align="char"><offsets xml_i="18284" xml_f="18286" txt_i="9606" txt_f="9608">15</offsets></td><td align="left"><offsets xml_i="18308" xml_f="18309" txt_i="9609" txt_f="9610">8</offsets></td></tr><tr><td align="left"><offsets xml_i="18340" xml_f="18361" txt_i="9611" txt_f="9632">Class 1: seizure free</offsets></td><td char="(" align="char"><offsets xml_i="18392" xml_f="18399" txt_i="9633" txt_f="9640">13 (87)</offsets></td><td align="left"><offsets xml_i="18421" xml_f="18427" txt_i="9641" txt_f="9647">6 (75)</offsets></td></tr><tr><td align="left"><offsets xml_i="18458" xml_f="18480" txt_i="9648" txt_f="9670">Class 2: rare seizures</offsets></td><td char="(" align="char"><offsets xml_i="18511" xml_f="18517" txt_i="9671" txt_f="9677">2 (12)</offsets></td><td align="left"><offsets xml_i="18539" xml_f="18545" txt_i="9678" txt_f="9684">2 (25)</offsets></td></tr><tr><td align="left"><offsets xml_i="18576" xml_f="18607" txt_i="9685" txt_f="9716">Class 3: meaningful improvement</offsets></td><td char="(" align="char"><offsets xml_i="18638" xml_f="18639" txt_i="9717" txt_f="9718">0</offsets></td><td align="left"><offsets xml_i="18661" xml_f="18662" txt_i="9719" txt_f="9720">0</offsets></td></tr><tr><td align="left"><offsets xml_i="18693" xml_f="18716" txt_i="9721" txt_f="9744">Class 4: no improvement</offsets></td><td char="(" align="char"><offsets xml_i="18747" xml_f="18748" txt_i="9745" txt_f="9746">0</offsets></td><td align="left"><offsets xml_i="18770" xml_f="18771" txt_i="9747" txt_f="9748">0</offsets></td></tr></tbody></table></table-wrap></p><p><offsets xml_i="18817" xml_f="18823" txt_i="9750" txt_f="9756">Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="18857" xml_f="18858" txt_i="9756" txt_f="9757">3</offsets></xref><offsets xml_i="18865" xml_f="19471" txt_i="9757" txt_f="10363"> shows the SEs reported in the telephone questionnaires administered ~3 and 6 months after surgery. The most prominent difference between the LEV and PHT groups in terms of SEs was difficulty with coordination: no patient in the LEV group reported this difficulty, compared to 4 (57%) and 2 (29%) of the PHT group at 3 and 6 months, respectively. The one patient taking LEV 1,500 mg twice a day did not report more SEs than those taking 500 mg twice a day, suggesting that LEV dosage does not correlate with increased SEs. No SEs in any study patient resulted in a hospitalization or withdrawal from study.</offsets><table-wrap id="Tab3"><label><offsets xml_i="19500" xml_f="19507" txt_i="10363" txt_f="10370">Table 3</offsets></label><caption><p><offsets xml_i="19527" xml_f="19566" txt_i="10370" txt_f="10409">Results of patient questionnaire on SEs</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"></th><th align="left" colspan="2"><offsets xml_i="19691" xml_f="19713" txt_i="10410" txt_f="10432">3 months postoperation</offsets></th><th align="left" colspan="2"><offsets xml_i="19747" xml_f="19769" txt_i="10432" txt_f="10454">6 months postoperation</offsets></th></tr><tr><th align="left"><offsets xml_i="19800" xml_f="19812" txt_i="10454" txt_f="10466">LEV patients</offsets><break></break><offsets xml_i="19827" xml_f="19832" txt_i="10466" txt_f="10471">n (%)</offsets></th><th align="left"><offsets xml_i="19854" xml_f="19866" txt_i="10471" txt_f="10483">PHT patients</offsets><break></break><offsets xml_i="19881" xml_f="19886" txt_i="10483" txt_f="10488">n (%)</offsets></th><th align="left"><offsets xml_i="19908" xml_f="19920" txt_i="10488" txt_f="10500">LEV patients</offsets><break></break><offsets xml_i="19935" xml_f="19940" txt_i="10500" txt_f="10505">n (%)</offsets></th><th align="left"><offsets xml_i="19962" xml_f="19974" txt_i="10505" txt_f="10517">PHT patients</offsets><break></break><offsets xml_i="19989" xml_f="19994" txt_i="10517" txt_f="10522">n (%)</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="20040" xml_f="20061" txt_i="10522" txt_f="10543">Number of respondents</offsets></td><td align="left"><offsets xml_i="20083" xml_f="20085" txt_i="10544" txt_f="10546">15</offsets></td><td align="left"><offsets xml_i="20107" xml_f="20108" txt_i="10547" txt_f="10548">7</offsets></td><td align="left"><offsets xml_i="20130" xml_f="20132" txt_i="10549" txt_f="10551">15</offsets></td><td align="left"><offsets xml_i="20154" xml_f="20155" txt_i="10552" txt_f="10553">7</offsets></td></tr><tr><td align="left" colspan="5"><italic><offsets xml_i="20206" xml_f="20239" txt_i="10554" txt_f="10587">Questions regarding potential SEs</offsets></italic></td></tr><tr><td align="left" colspan="5"><offsets xml_i="20291" xml_f="20348" txt_i="10588" txt_f="10645">Have you been experiencing any of the following symptoms?</offsets></td></tr><tr><td align="left"><offsets xml_i="20379" xml_f="20392" txt_i="10646" txt_f="10659">    Dizziness</offsets></td><td align="left"><offsets xml_i="20414" xml_f="20419" txt_i="10660" txt_f="10665">1 (7)</offsets></td><td align="left"><offsets xml_i="20441" xml_f="20442" txt_i="10666" txt_f="10667">0</offsets></td><td align="left"><offsets xml_i="20464" xml_f="20465" txt_i="10668" txt_f="10669">0</offsets></td><td align="left"><offsets xml_i="20487" xml_f="20493" txt_i="10670" txt_f="10676">1 (14)</offsets></td></tr><tr><td align="left"><offsets xml_i="20524" xml_f="20536" txt_i="10677" txt_f="10689">    Headache</offsets></td><td align="left"><offsets xml_i="20558" xml_f="20563" txt_i="10690" txt_f="10695">1 (7)</offsets></td><td align="left"><offsets xml_i="20585" xml_f="20591" txt_i="10696" txt_f="10702">1 (14)</offsets></td><td align="left"><offsets xml_i="20613" xml_f="20618" txt_i="10703" txt_f="10708">1 (7)</offsets></td><td align="left"><offsets xml_i="20640" xml_f="20646" txt_i="10709" txt_f="10715">1 (14)</offsets></td></tr><tr><td align="left"><offsets xml_i="20677" xml_f="20709" txt_i="10716" txt_f="10748">    Difficulty with coordination</offsets></td><td align="left"><offsets xml_i="20731" xml_f="20732" txt_i="10749" txt_f="10750">0</offsets></td><td align="left"><offsets xml_i="20754" xml_f="20760" txt_i="10751" txt_f="10757">4 (57)</offsets></td><td align="left"><offsets xml_i="20782" xml_f="20783" txt_i="10758" txt_f="10759">0</offsets></td><td align="left"><offsets xml_i="20805" xml_f="20811" txt_i="10760" txt_f="10766">2 (29)</offsets></td></tr><tr><td align="left"><offsets xml_i="20842" xml_f="20866" txt_i="10767" txt_f="10791">    Excessive sleepiness</offsets></td><td align="left"><offsets xml_i="20888" xml_f="20894" txt_i="10792" txt_f="10798">3 (20)</offsets></td><td align="left"><offsets xml_i="20916" xml_f="20922" txt_i="10799" txt_f="10805">2 (29)</offsets></td><td align="left"><offsets xml_i="20944" xml_f="20950" txt_i="10806" txt_f="10812">3 (20)</offsets></td><td align="left"><offsets xml_i="20972" xml_f="20978" txt_i="10813" txt_f="10819">2 (29)</offsets></td></tr><tr><td align="left"><offsets xml_i="21009" xml_f="21026" txt_i="10820" txt_f="10837">    Enlarged gums</offsets></td><td align="left"><offsets xml_i="21048" xml_f="21049" txt_i="10838" txt_f="10839">0</offsets></td><td align="left"><offsets xml_i="21071" xml_f="21072" txt_i="10840" txt_f="10841">0</offsets></td><td align="left"><offsets xml_i="21094" xml_f="21095" txt_i="10842" txt_f="10843">0</offsets></td><td align="left"><offsets xml_i="21117" xml_f="21118" txt_i="10844" txt_f="10845">0</offsets></td></tr><tr><td align="left"><offsets xml_i="21149" xml_f="21163" txt_i="10846" txt_f="10860">    Depression</offsets></td><td align="left"><offsets xml_i="21185" xml_f="21190" txt_i="10861" txt_f="10866">1 (7)</offsets></td><td align="left"><offsets xml_i="21212" xml_f="21218" txt_i="10867" txt_f="10873">1 (14)</offsets></td><td align="left"><offsets xml_i="21240" xml_f="21245" txt_i="10874" txt_f="10879">1 (7)</offsets></td><td align="left"><offsets xml_i="21267" xml_f="21273" txt_i="10880" txt_f="10886">1 (14)</offsets></td></tr><tr><td align="left"><offsets xml_i="21304" xml_f="21327" txt_i="10887" txt_f="10910">    Difficulty sleeping</offsets></td><td align="left"><offsets xml_i="21349" xml_f="21355" txt_i="10911" txt_f="10917">5 (33)</offsets></td><td align="left"><offsets xml_i="21377" xml_f="21383" txt_i="10918" txt_f="10924">1 (14)</offsets></td><td align="left"><offsets xml_i="21405" xml_f="21411" txt_i="10925" txt_f="10931">6 (40)</offsets></td><td align="left"><offsets xml_i="21433" xml_f="21439" txt_i="10932" txt_f="10938">3 (43)</offsets></td></tr><tr><td align="left"><offsets xml_i="21470" xml_f="21483" txt_i="10939" txt_f="10952">    Itchiness</offsets></td><td align="left"><offsets xml_i="21505" xml_f="21506" txt_i="10953" txt_f="10954">0</offsets></td><td align="left"><offsets xml_i="21528" xml_f="21534" txt_i="10955" txt_f="10961">1 (14)</offsets></td><td align="left"><offsets xml_i="21556" xml_f="21557" txt_i="10962" txt_f="10963">0</offsets></td><td align="left"><offsets xml_i="21579" xml_f="21580" txt_i="10964" txt_f="10965">0</offsets></td></tr><tr><td align="left"><offsets xml_i="21611" xml_f="21621" txt_i="10966" txt_f="10976">    Nausea</offsets></td><td align="left"><offsets xml_i="21643" xml_f="21644" txt_i="10977" txt_f="10978">0</offsets></td><td align="left"><offsets xml_i="21666" xml_f="21667" txt_i="10979" txt_f="10980">0</offsets></td><td align="left"><offsets xml_i="21689" xml_f="21690" txt_i="10981" txt_f="10982">0</offsets></td><td align="left"><offsets xml_i="21712" xml_f="21713" txt_i="10983" txt_f="10984">0</offsets></td></tr><tr><td align="left"><offsets xml_i="21744" xml_f="21756" txt_i="10985" txt_f="10997">    Vomiting</offsets></td><td align="left"><offsets xml_i="21778" xml_f="21779" txt_i="10998" txt_f="10999">0</offsets></td><td align="left"><offsets xml_i="21801" xml_f="21802" txt_i="11000" txt_f="11001">0</offsets></td><td align="left"><offsets xml_i="21824" xml_f="21825" txt_i="11002" txt_f="11003">0</offsets></td><td align="left"><offsets xml_i="21847" xml_f="21848" txt_i="11004" txt_f="11005">0</offsets></td></tr><tr><td align="left"><offsets xml_i="21879" xml_f="21921" txt_i="11006" txt_f="11048">    Tingling, “pins and needles” sensation</offsets></td><td align="left"><offsets xml_i="21943" xml_f="21944" txt_i="11049" txt_f="11050">0</offsets></td><td align="left"><offsets xml_i="21966" xml_f="21972" txt_i="11051" txt_f="11057">1 (14)</offsets></td><td align="left"><offsets xml_i="21994" xml_f="21995" txt_i="11058" txt_f="11059">0</offsets></td><td align="left"><offsets xml_i="22017" xml_f="22018" txt_i="11060" txt_f="11061">0</offsets></td></tr><tr><td align="left"><offsets xml_i="22049" xml_f="22064" txt_i="11062" txt_f="11077">    Nervousness</offsets></td><td align="left"><offsets xml_i="22086" xml_f="22091" txt_i="11078" txt_f="11083">1 (7)</offsets></td><td align="left"><offsets xml_i="22113" xml_f="22119" txt_i="11084" txt_f="11090">1 (14)</offsets></td><td align="left"><offsets xml_i="22141" xml_f="22142" txt_i="11091" txt_f="11092">0</offsets></td><td align="left"><offsets xml_i="22164" xml_f="22165" txt_i="11093" txt_f="11094">0</offsets></td></tr><tr><td align="left"><offsets xml_i="22196" xml_f="22221" txt_i="11095" txt_f="11120">    Emotional instability</offsets></td><td align="left"><offsets xml_i="22243" xml_f="22249" txt_i="11121" txt_f="11127">2 (13)</offsets></td><td align="left"><offsets xml_i="22271" xml_f="22272" txt_i="11128" txt_f="11129">0</offsets></td><td align="left"><offsets xml_i="22294" xml_f="22299" txt_i="11130" txt_f="11135">1 (7)</offsets></td><td align="left"><offsets xml_i="22321" xml_f="22322" txt_i="11136" txt_f="11137">0</offsets></td></tr><tr><td align="left"><offsets xml_i="22353" xml_f="22371" txt_i="11138" txt_f="11156">    Slurred speech</offsets></td><td align="left"><offsets xml_i="22393" xml_f="22398" txt_i="11157" txt_f="11162">1 (7)</offsets></td><td align="left"><offsets xml_i="22420" xml_f="22421" txt_i="11163" txt_f="11164">0</offsets></td><td align="left"><offsets xml_i="22443" xml_f="22449" txt_i="11165" txt_f="11171">2 (13)</offsets></td><td align="left"><offsets xml_i="22471" xml_f="22472" txt_i="11172" txt_f="11173">0</offsets></td></tr><tr><td align="left"><offsets xml_i="22503" xml_f="22533" txt_i="11174" txt_f="11204">    Lack of Energy or Strength</offsets></td><td align="left"><offsets xml_i="22555" xml_f="22561" txt_i="11205" txt_f="11211">4 (27)</offsets></td><td align="left"><offsets xml_i="22583" xml_f="22589" txt_i="11212" txt_f="11218">4 (57)</offsets></td><td align="left"><offsets xml_i="22611" xml_f="22617" txt_i="11219" txt_f="11225">3 (20)</offsets></td><td align="left"><offsets xml_i="22639" xml_f="22645" txt_i="11226" txt_f="11232">3 (43)</offsets></td></tr><tr><td align="left"><offsets xml_i="22676" xml_f="22692" txt_i="11233" txt_f="11249">    Constipation</offsets></td><td align="left"><offsets xml_i="22714" xml_f="22715" txt_i="11250" txt_f="11251">0</offsets></td><td align="left"><offsets xml_i="22737" xml_f="22743" txt_i="11252" txt_f="11258">1 (14)</offsets></td><td align="left"><offsets xml_i="22765" xml_f="22766" txt_i="11259" txt_f="11260">0</offsets></td><td align="left"><offsets xml_i="22788" xml_f="22789" txt_i="11261" txt_f="11262">0</offsets></td></tr><tr><td align="left"><offsets xml_i="22820" xml_f="22850" txt_i="11263" txt_f="11293">    Difficulty keeping balance</offsets></td><td align="left"><offsets xml_i="22872" xml_f="22873" txt_i="11294" txt_f="11295">0</offsets></td><td align="left"><offsets xml_i="22895" xml_f="22896" txt_i="11296" txt_f="11297">0</offsets></td><td align="left"><offsets xml_i="22918" xml_f="22919" txt_i="11298" txt_f="11299">0</offsets></td><td align="left"><offsets xml_i="22941" xml_f="22942" txt_i="11300" txt_f="11301">0</offsets></td></tr><tr><td align="left"><offsets xml_i="22973" xml_f="22981" txt_i="11302" txt_f="11310">    Rash</offsets></td><td align="left"><offsets xml_i="23003" xml_f="23004" txt_i="11311" txt_f="11312">0</offsets></td><td align="left"><offsets xml_i="23026" xml_f="23027" txt_i="11313" txt_f="11314">0</offsets></td><td align="left"><offsets xml_i="23049" xml_f="23050" txt_i="11315" txt_f="11316">0</offsets></td><td align="left"><offsets xml_i="23072" xml_f="23073" txt_i="11317" txt_f="11318">0</offsets></td></tr><tr><td align="left"><offsets xml_i="23104" xml_f="23187" txt_i="11319" txt_f="11402">    Have you been experiencing any other SEs that you attribute to your medication?</offsets></td><td align="left"><offsets xml_i="23209" xml_f="23215" txt_i="11403" txt_f="11409">3 (20)</offsets></td><td align="left"><offsets xml_i="23237" xml_f="23243" txt_i="11410" txt_f="11416">2 (29)</offsets></td><td align="left"><offsets xml_i="23265" xml_f="23271" txt_i="11417" txt_f="11423">2 (13)</offsets></td><td align="left"><offsets xml_i="23293" xml_f="23299" txt_i="11424" txt_f="11430">2 (29)</offsets></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4" sec-type="discussion"><title><offsets xml_i="23392" xml_f="23402" txt_i="11433" txt_f="11443">Discussion</offsets></title><p><offsets xml_i="23413" xml_f="23746" txt_i="11444" txt_f="11777">An ideal AED for brain tumor patients would be one that has few SEs and does not interfere with medications commonly used in brain tumor treatment. While PHT is very commonly used for seizure control in brain tumor patients, it has many undesirable pharmacological qualities. PHT induces the metabolism of the steroid dexamethasone [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="23779" xml_f="23781" txt_i="11777" txt_f="11779">11</offsets></xref><offsets xml_i="23788" xml_f="23790" txt_i="11779" txt_f="11781">, </offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="23823" xml_f="23825" txt_i="11781" txt_f="11783">13</offsets></xref><offsets xml_i="23832" xml_f="23881" txt_i="11783" txt_f="11832">], and dexamethasone decreases PHT serum levels [</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="23914" xml_f="23916" txt_i="11832" txt_f="11834">22</offsets></xref><offsets xml_i="23923" xml_f="23981" txt_i="11834" txt_f="11892">]. Certain chemotherapeutic agents also lower PHT levels [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="24014" xml_f="24016" txt_i="11892" txt_f="11894">12</offsets></xref><offsets xml_i="24023" xml_f="24207" txt_i="11894" txt_f="12078">], and, vice versa, PHT can accelerate the metabolism of a variety of chemotherapy drugs including nitrosoureas, paclitaxel, 9-aminocamptothecin, thiotepa, topotecan, and irinotecan ([</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="24239" xml_f="24240" txt_i="12078" txt_f="12079">1</offsets></xref><offsets xml_i="24247" xml_f="24249" txt_i="12079" txt_f="12081">, </offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="24282" xml_f="24284" txt_i="12081" txt_f="12083">14</offsets></xref><offsets xml_i="24291" xml_f="24368" txt_i="12083" txt_f="12160">] and references therein). In terms of SEs, PHT adversely affects cognition [</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="24401" xml_f="24403" txt_i="12160" txt_f="12162">23</offsets></xref><offsets xml_i="24410" xml_f="24412" txt_i="12162" txt_f="12164">, </offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="24445" xml_f="24447" txt_i="12164" txt_f="12166">24</offsets></xref><offsets xml_i="24454" xml_f="24598" txt_i="12166" txt_f="12310">], which is often already depressed in brain tumor patients. Furthermore, brain tumor patients taking PHT are at increased risk of drug rashes [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="24631" xml_f="24633" txt_i="12310" txt_f="12312">25</offsets></xref><offsets xml_i="24640" xml_f="24679" txt_i="12312" txt_f="12351">], including Stevens-Johnson syndrome [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="24712" xml_f="24714" txt_i="12351" txt_f="12353">26</offsets></xref><offsets xml_i="24721" xml_f="24791" txt_i="12353" txt_f="12423">], an immune-mediated rash associated with severe morbidity and death.</offsets></p><p><offsets xml_i="24798" xml_f="25128" txt_i="12424" txt_f="12754">Because LEV does not have any significant drug interactions, this AED poses fewer complications for the pharmacotherapy of brain tumors. A retrospective study of 34 patients with primary brain tumors suggested that LEV is effective and well tolerated for tumor-related seizure control, especially as add-on therapy to other AEDs [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="25161" xml_f="25163" txt_i="12754" txt_f="12756">19</offsets></xref><offsets xml_i="25170" xml_f="25341" txt_i="12756" txt_f="12927">]. Prospectively, LEV has been studied as add-on therapy for seizure control in brain tumor patients. In a cohort of 25 patients with primary brain tumors, Wagner et al. [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="25374" xml_f="25376" txt_i="12927" txt_f="12929">21</offsets></xref><offsets xml_i="25383" xml_f="25525" txt_i="12929" txt_f="13071">] found that add-on LEV reduced seizure frequency by more than 50% in 13 of the patients who experienced persistent seizures. Maschio et al. [</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="25558" xml_f="25560" txt_i="13071" txt_f="13073">20</offsets></xref><offsets xml_i="25567" xml_f="26065" txt_i="13073" txt_f="13571">] prospectively followed 19 patients with primary brain tumors who had LEV added to existing AED therapy on account of persisting seizures; in that study, 14 patients had improvement in seizure control. There have been no reports of serious SEs of LEV therapy in any of the studies of brain tumor patients to date. For the reasons described above, safe conversion of PHT to LEV monotherapy may provide significant clinical advantages for the post-surgical medical treatment of primary brain tumors.</offsets></p><p><offsets xml_i="26072" xml_f="26488" txt_i="13572" txt_f="13988">In our study population, LEV and PHT groups had similar proportions of seizure-free patients (87% and 75%, respectively) at 6 months of follow-up. These seizure control rates are in line with those observed in a retrospective analysis of low grade glioma patients treated at this institution; of 253 patients who had tumor-related seizures, 169 (67%) were seizure-free 6 months after craniotomy for tumor resection [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="26520" xml_f="26521" txt_i="13988" txt_f="13989">8</offsets></xref><offsets xml_i="26528" xml_f="26686" txt_i="13989" txt_f="14147">]. Thus, LEV and PHT groups had expected levels of seizure control. Furthermore, no patient in our study had seizures refractory to either LEV or PHT therapy.</offsets></p><p><offsets xml_i="26693" xml_f="28026" txt_i="14148" txt_f="15481">LEV and PHT were both well tolerated in our study population. Although difficulty with coordination is a potential SE for both LEV and PHT, no patient in the LEV study group (0/15) admitted to experiencing this difficulty while more than half of the PHT group (4/7) at 3 months reported this SE. Other known LEV SEs are somnolence and behavioral abnormalities. Both PHT and LEV groups had similar proportions of patients reporting somnolence. One subject in the LEV group reported feeling unusually hostile towards others after starting LEV therapy; however, this behavioral change did not require the discontinuation of LEV. No PHT study subject admitted to experiencing any emotional instability at any time point. In placebo-controlled trials of LEV for partial-onset epilepsy, LEV was associated with a 0.7% incidence of psychosis as compared to 0.2% for placebo patients. Although Maschio et al. reported that there were no LEV-related SEs observed in their study of primary brain tumor patients, Wagner et al. did report one patient in their study of 26 who developed a psychosis 4 weeks after initiating LEV therapy which resulted in discontinuation of this AED. Given the report of psychosis in Wagner et al. and our findings of emotional instability in up to 13% of our LEV group as compared to none in the PHT group (Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="28060" xml_f="28061" txt_i="15481" txt_f="15482">2</offsets></xref><offsets xml_i="28068" xml_f="28191" txt_i="15482" txt_f="15605">), we suggest that it would be important to evaluate brain tumor patients on LEV therapy for potential behavioral problems.</offsets></p><p><offsets xml_i="28198" xml_f="28636" txt_i="15606" txt_f="16044">Our pilot data presented here suggest that it is safe and feasible to switch from PHT to LEV monotherapy after craniotomy for glioma-related seizures. Due to the small size of our study, the data presented here cannot serve as an official endorsement of LEV efficacy in this patient population. A large-scale, double-blinded, randomized controlled trial is warranted to compare PHT and LEV for seizure control equivalence and SE profiles.</offsets></p></sec></body><back><ack><title>Acknowledgment</title><p>This work was supported by a Young Investigator Research Program award to D.A.L. and M.W.M. from UCB Pharma.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glantz</surname><given-names>MJ</given-names></name><name><surname>Cole</surname><given-names>BF</given-names></name><name><surname>Forsyth</surname><given-names>PA</given-names></name><name><surname>Recht</surname><given-names>LD</given-names></name><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Chamberlain</surname><given-names>MC</given-names></name><name><surname>Grossman</surname><given-names>SA</given-names></name><name><surname>Cairncross</surname><given-names>JG</given-names></name></person-group><article-title>Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy Of Neurology</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>1886</fpage><lpage>1893</lpage></citation><citation citation-type="display-unstructured">Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy Of Neurology. Neurology 54:1886–1893 <pub-id pub-id-type="pmid">10822423</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Engelberts</surname><given-names>NH</given-names></name><name><surname>Ploeg</surname><given-names>HM</given-names></name><name><surname>Kasteleijn-Nolst Trenite</surname><given-names>DG</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Taphoorn</surname><given-names>MJ</given-names></name><name><surname>Baaijen</surname><given-names>H</given-names></name><name><surname>Vandertop</surname><given-names>WP</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><name><surname></surname><given-names>TJ</given-names></name><name><surname>Heimans</surname><given-names>JJ</given-names></name></person-group><article-title>Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life</article-title><source>Ann Neurol</source><year>2003</year><volume>54</volume><fpage>514</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1002/ana.10712</pub-id></citation><citation citation-type="display-unstructured">Klein M, Engelberts NH, van der Ploeg HM, Kasteleijn-Nolst Trenite DG, Aaronson NK, Taphoorn MJ, Baaijen H, Vandertop WP, Muller M, Postma TJ, Heimans JJ (2003) Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54:514–520. doi:10.1002/ana.10712 <pub-id pub-id-type="pmid">14520665</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>KD</given-names></name></person-group><article-title>Efficacy, pharmacology, and adverse effects of antiepileptic drugs</article-title><source>Neurol Clin</source><year>2001</year><volume>19</volume><fpage>313</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1016/S0733-8619(05)70021-9</pub-id></citation><citation citation-type="display-unstructured">Holland KD (2001) Efficacy, pharmacology, and adverse effects of antiepileptic drugs. Neurol Clin 19:313–345. doi:10.1016/S0733-8619(05)70021-9 <pub-id pub-id-type="pmid">11358747</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schachater</surname><given-names>SC</given-names></name></person-group><article-title>Epilepsy</article-title><source>Neurol Clin</source><year>2001</year><volume>19</volume><fpage>57</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/S0733-8619(05)70005-0</pub-id></citation><citation citation-type="display-unstructured">Schachater SC (2001) Epilepsy. Neurol Clin 19:57–78. doi:10.1016/S0733-8619(05)70005-0 <pub-id pub-id-type="pmid">11471768</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Marks</surname><given-names>PW</given-names></name></person-group><article-title>Medical management of patients with brain tumors</article-title><source>Curr Opin Oncol</source><year>2002</year><volume>14</volume><fpage>299</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1097/00001622-200205000-00008</pub-id></citation><citation citation-type="display-unstructured">Wen PY, Marks PW (2002) Medical management of patients with brain tumors. Curr Opin Oncol 14:299–307. doi:10.1097/00001622-200205000-00008 <pub-id pub-id-type="pmid">11981275</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="other">Chang EF, Keles GE, Chang SM, Lamborn KL, Barbaro NM, Berger MS (2005) Seizure characteristics and post-operative seizure control in patients with low-grade gliomas. Congress of Neurological Surgeons (abstract) 2005. Los Angeles, CA, USA</citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Franceschetti</surname><given-names>S</given-names></name><name><surname>Binelli</surname><given-names>S</given-names></name><name><surname>Casazza</surname><given-names>M</given-names></name><name><surname>Lodrini</surname><given-names>S</given-names></name><name><surname>Panzica</surname><given-names>F</given-names></name><name><surname>Pluchino</surname><given-names>F</given-names></name><name><surname>Solero</surname><given-names>CL</given-names></name><name><surname>Avanzini</surname><given-names>G</given-names></name></person-group><article-title>Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours</article-title><source>Acta Neurochir (Wien)</source><year>1990</year><volume>103</volume><fpage>47</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/BF01420191</pub-id></citation><citation citation-type="display-unstructured">Franceschetti S, Binelli S, Casazza M, Lodrini S, Panzica F, Pluchino F, Solero CL, Avanzini G (1990) Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir (Wien) 103:47–51. doi:10.1007/BF01420191 <pub-id pub-id-type="pmid">2360466</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>EF</given-names></name><name><surname>Potts</surname><given-names>MB</given-names></name><name><surname>Keles</surname><given-names>GE</given-names></name><name><surname>Lamborn</surname><given-names>KR</given-names></name><name><surname>Chang</surname><given-names>SM</given-names></name><name><surname>Barbaro</surname><given-names>NM</given-names></name><name><surname>Berger</surname><given-names>MS</given-names></name></person-group><article-title>Seizure characteristics and control following resection in 332 patients with low-grade gliomas</article-title><source>J Neurosurg</source><year>2008</year><volume>108</volume><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.3171/JNS/2008/108/2/0227</pub-id></citation><citation citation-type="display-unstructured">Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, Berger MS (2008) Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 108:227–235. doi:10.3171/JNS/2008/108/2/0227 <pub-id pub-id-type="pmid">18240916</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>North</surname><given-names>JB</given-names></name><name><surname>Penhall</surname><given-names>RK</given-names></name><name><surname>Hanieh</surname><given-names>A</given-names></name><name><surname>Frewin</surname><given-names>DB</given-names></name><name><surname>Taylor</surname><given-names>WB</given-names></name></person-group><article-title>Phenytoin and postoperative epilepsy. A double-blind study</article-title><source>J Neurosurg</source><year>1983</year><volume>58</volume><fpage>672</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.3171/jns.1983.58.5.0672</pub-id></citation><citation citation-type="display-unstructured">North JB, Penhall RK, Hanieh A, Frewin DB, Taylor WB (1983) Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg 58:672–677 <pub-id pub-id-type="pmid">6339686</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>MD</given-names></name><name><surname>Foy</surname><given-names>PM</given-names></name></person-group><article-title>Epilepsy after craniotomy and the place of prophylactic anticonvulsant drugs: discussion paper</article-title><source>J R Soc Med</source><year>1991</year><volume>84</volume><fpage>221</fpage><lpage>223</lpage></citation><citation citation-type="display-unstructured">Shaw MD, Foy PM (1991) Epilepsy after craniotomy and the place of prophylactic anticonvulsant drugs: discussion paper. J R Soc Med 84:221–223 <pub-id pub-id-type="pmid">2027149</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chalk</surname><given-names>JB</given-names></name><name><surname>Ridgeway</surname><given-names>K</given-names></name><name><surname>Brophy</surname><given-names>T</given-names></name><name><surname>Yelland</surname><given-names>JD</given-names></name><name><surname>Eadie</surname><given-names>MJ</given-names></name></person-group><article-title>Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1984</year><volume>47</volume><fpage>1087</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1136/jnnp.47.10.1087</pub-id></citation><citation citation-type="display-unstructured">Chalk JB, Ridgeway K, Brophy T, Yelland JD, Eadie MJ (1984) Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry 47:1087–1090. doi:10.1136/jnnp.47.10.1087 <pub-id pub-id-type="pmid">6502166</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>SA</given-names></name><name><surname>Sheidler</surname><given-names>VR</given-names></name><name><surname>Gilbert</surname><given-names>MR</given-names></name></person-group><article-title>Decreased phenytoin levels in patients receiving chemotherapy</article-title><source>Am J Med</source><year>1989</year><volume>87</volume><fpage>505</fpage><lpage>510</lpage></citation><citation citation-type="display-unstructured">Grossman SA, Sheidler VR, Gilbert MR (1989) Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 87:505–510 <pub-id pub-id-type="pmid">2683764</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Werk</surname><given-names>EE</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Sholiton</surname><given-names>L</given-names></name><name><surname>Olinger</surname><given-names>C</given-names></name><name><surname>Haque</surname><given-names>N</given-names></name></person-group><article-title>Interference in the effect of dexamethasone by diphenylhydantoin</article-title><source>N Engl J Med</source><year>1969</year><volume>281</volume><fpage>32</fpage><lpage>34</lpage></citation><citation citation-type="display-unstructured">Werk EE Jr, Choi Y, Sholiton L, Olinger C, Haque N (1969) Interference in the effect of dexamethasone by diphenylhydantoin. N Engl J Med 281:32–34 <pub-id pub-id-type="pmid">5814988</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Breemen</surname><given-names>MS</given-names></name><name><surname>Wilms</surname><given-names>EB</given-names></name><name><surname>Vecht</surname><given-names>CJ</given-names></name></person-group><article-title>Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management</article-title><source>Lancet Neurol</source><year>2007</year><volume>6</volume><fpage>421</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(07)70103-5</pub-id></citation><citation citation-type="display-unstructured">van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421–430. doi:10.1016/S1474-4422(07)70103-5 <pub-id pub-id-type="pmid">17434097</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patsalos</surname><given-names>PN</given-names></name></person-group><article-title>Clinical pharmacokinetics of levetiracetam</article-title><source>Clin Pharmacokinet</source><year>2004</year><volume>43</volume><fpage>707</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.2165/00003088-200443110-00002</pub-id></citation><citation citation-type="display-unstructured">Patsalos PN (2004) Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 43:707–724. doi:10.2165/00003088-200443110-00002 <pub-id pub-id-type="pmid">15301575</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welty</surname><given-names>TE</given-names></name><name><surname>Gidal</surname><given-names>BE</given-names></name><name><surname>Ficker</surname><given-names>DM</given-names></name><name><surname>Privitera</surname><given-names>MD</given-names></name></person-group><article-title>Levetiracetam: a different approach to the pharmacotherapy of epilepsy</article-title><source>Ann Pharmacother</source><year>2002</year><volume>36</volume><fpage>296</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1345/aph.1A032</pub-id></citation><citation citation-type="display-unstructured">Welty TE, Gidal BE, Ficker DM, Privitera MD (2002) Levetiracetam: a different approach to the pharmacotherapy of epilepsy. Ann Pharmacother 36:296–304. doi:10.1345/aph.1A032 <pub-id pub-id-type="pmid">11847952</pub-id></citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Contin</surname><given-names>M</given-names></name><name><surname>Albani</surname><given-names>F</given-names></name><name><surname>Riva</surname><given-names>R</given-names></name><name><surname>Baruzzi</surname><given-names>A</given-names></name></person-group><article-title>Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs</article-title><source>Ther Drug Monit</source><year>2004</year><volume>26</volume><fpage>375</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1097/00007691-200408000-00006</pub-id></citation><citation citation-type="display-unstructured">Contin M, Albani F, Riva R, Baruzzi A (2004) Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit 26:375–379. doi:10.1097/00007691-200408000-00006 <pub-id pub-id-type="pmid">15257066</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>HB</given-names></name><name><surname>Dalton</surname><given-names>J</given-names></name><name><surname>Goldlust</surname><given-names>S</given-names></name><name><surname>Pearl</surname><given-names>D</given-names></name></person-group><article-title>Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors</article-title><source>J Neurooncol</source><year>2007</year><volume>84</volume><fpage>293</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1007/s11060-007-9373-8</pub-id></citation><citation citation-type="display-unstructured">Newton HB, Dalton J, Goldlust S, Pearl D (2007) Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol 84:293–296. doi:10.1007/s11060-007-9373-8 <pub-id pub-id-type="pmid">17431542</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>HB</given-names></name><name><surname>Goldlust</surname><given-names>SA</given-names></name><name><surname>Pearl</surname><given-names>D</given-names></name></person-group><article-title>Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients</article-title><source>J Neurooncol</source><year>2006</year><volume>78</volume><fpage>99</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1007/s11060-005-9070-4</pub-id></citation><citation citation-type="display-unstructured">Newton HB, Goldlust SA, Pearl D (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78:99–102. doi:10.1007/s11060-005-9070-4 <pub-id pub-id-type="pmid">16541329</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="other">Maschio M, Albani F, Baruzzi A, Zarabla A, Dinapoli L, Pace A, Pompili A, Carapella CM, Occhipinti E, Jandolo B (2006) Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 78:157–160</citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>GL</given-names></name><name><surname>Wilms</surname><given-names>EB</given-names></name><name><surname>Donselaar</surname><given-names>CA</given-names></name><name><surname>Vecht</surname><given-names>ChJ</given-names></name></person-group><article-title>Levetiracetam: preliminary experience in patients with primary brain tumours</article-title><source>Seizure</source><year>2003</year><volume>12</volume><fpage>585</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1016/S1059-1311(03)00096-7</pub-id></citation><citation citation-type="display-unstructured">Wagner GL, Wilms EB, Van Donselaar CA, Vecht ChJ (2003) Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 12:585–586. doi:10.1016/S1059-1311(03)00096-7 <pub-id pub-id-type="pmid">14630498</pub-id></citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname><given-names>LA</given-names></name><name><surname>Blouin</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>RB</given-names></name><name><surname>Rapp</surname><given-names>RP</given-names></name><name><surname>Young</surname><given-names>AB</given-names></name></person-group><article-title>Phenytoin-dexamethasone interaction: a previously unreported observation</article-title><source>Surg Neurol</source><year>1981</year><volume>16</volume><fpage>23</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/S0090-3019(81)80054-7</pub-id></citation><citation citation-type="display-unstructured">Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB (1981) Phenytoin-dexamethasone interaction: a previously unreported observation. Surg Neurol 16:23–24. doi:10.1016/S0090-3019(81)80054-7 <pub-id pub-id-type="pmid">7280966</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akaho</surname><given-names>R</given-names></name></person-group><article-title>The effects of antiepileptic drugs on cognition in normal volunteers</article-title><source>Psychiatry Clin Neurosci</source><year>1996</year><volume>50</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1819.1996.tb01665.x</pub-id></citation><citation citation-type="display-unstructured">Akaho R (1996) The effects of antiepileptic drugs on cognition in normal volunteers. Psychiatry Clin Neurosci 50:61–69. doi:10.1111/j.1440-1819.1996.tb01665.x <pub-id pub-id-type="pmid">8783377</pub-id></citation></ref><ref id="CR24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drane</surname><given-names>DL</given-names></name><name><surname>Meador</surname><given-names>KJ</given-names></name></person-group><article-title>Cognitive and behavioral effects of antiepileptic drugs</article-title><source>Epilepsy Behav</source><year>2002</year><volume>3</volume><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/S1525-5069(02)00502-9</pub-id></citation><citation citation-type="display-unstructured">Drane DL, Meador KJ (2002) Cognitive and behavioral effects of antiepileptic drugs. Epilepsy Behav 3:49–53. doi:10.1016/S1525-5069(02)00502-9 <pub-id pub-id-type="pmid">12609322</pub-id></citation></ref><ref id="CR25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mamon</surname><given-names>HJ</given-names></name><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Burns</surname><given-names>AC</given-names></name><name><surname>Loeffler</surname><given-names>JS</given-names></name></person-group><article-title>Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy</article-title><source>Epilepsia</source><year>1999</year><volume>40</volume><fpage>341</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1157.1999.tb00715.x</pub-id></citation><citation citation-type="display-unstructured">Mamon HJ, Wen PY, Burns AC, Loeffler JS (1999) Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia 40:341–344. doi:10.1111/j.1528-1157.1999.tb00715.x <pub-id pub-id-type="pmid">10080516</pub-id></citation></ref><ref id="CR26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delattre</surname><given-names>JY</given-names></name><name><surname>Safai</surname><given-names>B</given-names></name><name><surname>Posner</surname><given-names>JB</given-names></name></person-group><article-title>Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin</article-title><source>Neurology</source><year>1988</year><volume>38</volume><fpage>194</fpage><lpage>198</lpage></citation><citation citation-type="display-unstructured">Delattre JY, Safai B, Posner JB (1988) Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 38:194–198 <pub-id pub-id-type="pmid">3340279</pub-id></citation></ref></ref-list></back></article>